Despite being approved in Europe, Oncopeptides' Pepaxto will remain sidelined in the US

In an FDA advisory committee meeting on Thursday afternoon, few punches were pulled as oncology experts assessed Oncopeptides’ multiple myeloma treatment Pepaxto (melflufen).